Akèy › Maladi Crohn › Kentucky
Etid klinik pou Maladi Crohn nan Kentucky
12 etid pou Maladi Crohn ap chèche patisipan nan sit nan Kentucky.
Vil nan Kentucky
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Louisville Hospital ( Site 5120), Louisville
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284144, Louisville
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Tri-State Gastroenterology Associates, Crestview Hills
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Kentucky Chandler Medical Center /ID# 265564, Lexington
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
- University of Louisville - MedCenter One, Louisville
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Of Louisville, Louisville
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Health Partners, Louisville
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University of Kentucky Hospital/UK Albert B. Chandler Hospital-Site Number: 8400058, Lexington
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Louisville, Louisville
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843Treatment of Moderate to Severe Refractory Crohn's Disease
- University of Louisville, Louisville
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Dec 10, 2025 · NCT06721962Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.